FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CDKN2B-DGKD

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CDKN2B-DGKD
FusionPDB ID: 15416
FusionGDB2.0 ID: 15416
HgeneTgene
Gene symbol

CDKN2B

DGKD

Gene ID

1030

8527

Gene namecyclin dependent kinase inhibitor 2Bdiacylglycerol kinase delta
SynonymsCDK4I|INK4B|MTS2|P15|TP15|p15INK4bDGK-delta|DGKdelta|dgkd-2
Cytomap

9p21.3

2q37.1

Type of geneprotein-codingprotein-coding
Descriptioncyclin-dependent kinase 4 inhibitor BCDK inhibitory proteinCDK4B inhibitorMTS-2cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)cyclin-dependent kinases 4 and 6 binding proteinmultiple tumor suppressor 2p14-INK4bp14_CDK inhibitorp14_INK4Bdiacylglycerol kinase deltaDAG kinase deltadiacylglycerol kinase, delta 130kDadiglyceride kinase delta
Modification date2020032220200313
UniProtAcc

P42772

Main function of 5'-partner protein: FUNCTION: Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.

Q16760

Main function of 5'-partner protein: FUNCTION: Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:12200442, PubMed:23949095). Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (Probable). By controlling the levels of diacylglycerol, regulates for instance the PKC and EGF receptor signaling pathways and plays a crucial role during development (By similarity). May also regulate clathrin-dependent endocytosis (PubMed:17880279). {ECO:0000250|UniProtKB:E9PUQ8, ECO:0000269|PubMed:12200442, ECO:0000269|PubMed:17880279, ECO:0000269|PubMed:23949095, ECO:0000305}.
Ensembl transtripts involved in fusion geneENST idsENST00000276925, ENST00000380142, 
ENST00000539462, 
ENST00000489613, 
ENST00000409813, ENST00000264057, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score2 X 2 X 2=83 X 3 X 3=27
# samples 23
** MAII scorelog2(2/8*10)=1.32192809488736log2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: CDKN2B [Title/Abstract] AND DGKD [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CDKN2B [Title/Abstract] AND DGKD [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CDKN2B(22008797)-DGKD(234296903), # samples:1
Anticipated loss of major functional domain due to fusion event.CDKN2B-DGKD seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CDKN2B-DGKD seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CDKN2B-DGKD seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CDKN2B-DGKD seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CDKN2B-DGKD seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
CDKN2B-DGKD seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
CDKN2B-DGKD seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCDKN2B

GO:0000079

regulation of cyclin-dependent protein serine/threonine kinase activity

8078588

HgeneCDKN2B

GO:0042326

negative regulation of phosphorylation

8078588

TgeneDGKD

GO:0010033

response to organic substance

12200442



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:22008797/chr2:234296903)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CDKN2B (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across DGKD (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000276925CDKN2Bchr922008797-ENST00000264057DGKDchr2234296903+669556618540541289

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000276925ENST00000264057CDKN2Bchr922008797-DGKDchr2234296903+0.0017308610.9982691

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CDKN2B-DGKD

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CDKN2Bchr922008797DGKDchr2234296903566126DPNGVNRFGRRAIQTIIKEGMLTKQN

Top

Potential FusionNeoAntigen Information of CDKN2B-DGKD in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CDKN2B-DGKD_22008797_234296903.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:05RRAIQTIIK0.99930.8965918
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:04RRAIQTIIK0.99490.8397918
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:04GRRAIQTII0.99420.831817
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:14RRAIQTIIK0.99820.8015918
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:14GRRAIQTII0.99280.7895817
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:03RRAIQTIIK0.98350.9053918
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:14GRRAIQTIIK0.99890.8742818
CDKN2B-DGKDchr922008797chr2234296903566HLA-B73:01NRFGRRAIQT0.99430.8632515
CDKN2B-DGKDchr922008797chr2234296903566HLA-B73:01NRFGRRAIQTI0.99830.7724516
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:10RRAIQTIIK0.9990.9304918
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:08RRAIQTIIK0.99840.7699918
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:06GRRAIQTII0.99730.8496817
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:09GRRAIQTII0.99490.8042817
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:10GRRAIQTII0.9940.9166817
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:08GRRAIQTII0.99270.7386817
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:10GRRAIQTIIK0.99870.9345818
CDKN2B-DGKDchr922008797chr2234296903566HLA-B27:06NRFGRRAIQTI0.99990.5127516

Top

Potential FusionNeoAntigen Information of CDKN2B-DGKD in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CDKN2B-DGKD_22008797_234296903.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1102PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1102DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1103DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1116PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1116DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1121PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1121DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1136PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1136DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1148DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1148PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1155PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1155DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1163DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1165PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1165DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1170PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1170DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1176DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1185DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1301PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1301DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1304DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1304PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1308DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1308PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1315PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1315DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1317PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1317DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1319PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1319DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1320PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1320DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1322PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1322DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1324DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1332DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1335PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1335DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1343DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1343PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1348DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1351PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1351DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1352PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1352DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1353PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1353DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1354DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1354PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1357PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1357DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1359PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1359DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1361PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1364PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1364DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1368PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1368DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1369PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1369DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1370DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1370PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1372DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1372PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1375DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1376DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1376PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1377RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1378PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1378DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1379PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1379DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1380PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1380DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1383PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1383DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1384DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1384PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1387PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1387DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1391PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1391DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1392PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1392DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1393DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1393PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1398PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1398DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1401RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1404RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1411RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1416DPNGVNRFGRRAIQT015
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1416PNGVNRFGRRAIQTI116
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1426RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1428RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1431RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1432RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1434RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1435RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1445RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1454RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1455RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1458RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1460RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1461RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1462RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1464RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1465RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1470RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1471RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1472RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1475RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1481RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1482RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1486RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1487RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1488RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1490RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1495RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1497RRAIQTIIKEGMLTK924
CDKN2B-DGKDchr922008797chr2234296903566DRB1-1499RRAIQTIIKEGMLTK924

Top

Fusion breakpoint peptide structures of CDKN2B-DGKD

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7830RFGRRAIQTIIKEGCDKN2BDGKDchr922008797chr2234296903566

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CDKN2B-DGKD

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7830RFGRRAIQTIIKEG-7.9962-8.1096
HLA-B14:023BVN7830RFGRRAIQTIIKEG-5.70842-6.74372
HLA-B52:013W397830RFGRRAIQTIIKEG-6.83737-6.95077
HLA-B52:013W397830RFGRRAIQTIIKEG-4.4836-5.5189
HLA-A11:014UQ27830RFGRRAIQTIIKEG-10.0067-10.1201
HLA-A11:014UQ27830RFGRRAIQTIIKEG-9.03915-10.0745
HLA-A24:025HGA7830RFGRRAIQTIIKEG-6.56204-6.67544
HLA-A24:025HGA7830RFGRRAIQTIIKEG-5.42271-6.45801
HLA-B44:053DX87830RFGRRAIQTIIKEG-7.85648-8.89178
HLA-B44:053DX87830RFGRRAIQTIIKEG-5.3978-5.5112
HLA-A02:016TDR7830RFGRRAIQTIIKEG-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CDKN2B-DGKD

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CDKN2B-DGKDchr922008797chr2234296903515NRFGRRAIQTCGTTTCGGGAGGCGCGCGATCCAGACCATC
CDKN2B-DGKDchr922008797chr2234296903516NRFGRRAIQTICGTTTCGGGAGGCGCGCGATCCAGACCATCATC
CDKN2B-DGKDchr922008797chr2234296903817GRRAIQTIIAGGCGCGCGATCCAGACCATCATCAAA
CDKN2B-DGKDchr922008797chr2234296903818GRRAIQTIIKAGGCGCGCGATCCAGACCATCATCAAAGAG
CDKN2B-DGKDchr922008797chr2234296903918RRAIQTIIKCGCGCGATCCAGACCATCATCAAAGAG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CDKN2B-DGKDchr922008797chr2234296903015DPNGVNRFGRRAIQTCCCAACGGAGTCAACCGTTTCGGGAGGCGCGCGATCCAGACCATC
CDKN2B-DGKDchr922008797chr2234296903116PNGVNRFGRRAIQTIAACGGAGTCAACCGTTTCGGGAGGCGCGCGATCCAGACCATCATC
CDKN2B-DGKDchr922008797chr2234296903924RRAIQTIIKEGMLTKCGCGCGATCCAGACCATCATCAAAGAGGGGATGCTGACCAAACAG

Top

Information of the samples that have these potential fusion neoantigens of CDKN2B-DGKD

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
GBMCDKN2B-DGKDchr922008797ENST00000276925chr2234296903ENST00000264057TCGA-06-0155-01B

Top

Potential target of CAR-T therapy development for CDKN2B-DGKD

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CDKN2B-DGKD

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CDKN2B-DGKD

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource